Deanna Crawford
Nurse Practitioner · Wheelersburg, OHNPI 1134870660
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.0% of the total across 537 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 24.0% of the total. Among nurse practitioner clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 537 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$2K
- Johnson & Johnson$1K
- AstraZeneca$1K
- Novartis$716
- UCB, Inc.$679
- plus $2K from 20 others
What the payments were for
- Food & beverage$9,63296%
- Education$3974%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 124 | $2,411 |
| Amgen(2 entities) | 121 | $2,054 |
| Johnson & Johnson(2 entities) | 55 | $1,187 |
| AstraZeneca(2 entities) | 48 | $1,079 |
| Novartis | 54 | $716 |
| UCB, Inc. | 37 | $679 |
| Lilly USA, LLC | 33 | $562 |
| GSK | 21 | $347 |
| E.r. Squibb & Sons, L.L.C. | 17 | $323 |
| Mallinckrodt Hospital Products Inc. | 3 | $153 |
| Boehringer Ingelheim | 4 | $72 |
| Aurinia Pharma U.S., Inc. | 3 | $70 |
| Radius Health, Inc. | 2 | $52 |
| Novo Nordisk | 1 | $50 |
| ANI Pharmaceuticals, Inc. | 2 | $47 |
| Genentech USA, Inc. | 2 | $35 |
| Sanofi | 1 | $26 |
| Invivyd Inc | 1 | $25 |
| Pfizer | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Sobi, Inc | 1 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Bioventus LLC | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Janssen Scientific Affairs, LLC | 1 | $14 |
| Organon | 1 | $6 |
How this compares
$10,029 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 55 | $359,725 |
| Enbrel MiniEtanercept | 42 | $302,482 |
| OtezlaApremilast | 33 | $179,244 |
| Cimzia (2 Pack)Certolizumab Pegol | 14 | $135,286 |
| Humira(Cf) PenAdalimumab | 14 | $129,567 |
| EnbrelEtanercept | 20 | $106,734 |
| Orencia ClickjectAbatacept | 18 | $101,247 |
| Humira(Cf)Adalimumab | 11 | $81,194 |
| KevzaraSarilumab | 16 | $68,318 |
| OlumiantBaricitinib | 23 | $60,879 |
| Hydroxychloroquine Sulfate | 553 | $13,267 |
| RasuvoMethotrexate/Pf | 12 | $9,157 |
| MethotrexateMethotrexate Sodium | 420 | $5,602 |
| Leflunomide | 92 | $4,799 |
| Gabapentin | 291 | $3,454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $2,411 | $440,91966 claims |
| AmgenOtezla, Enbrel | $2,054 | $285,97753 claims |
| UCB, Inc.Cimzia (2 Pack) | $679 | $135,28614 claims |
| SanofiKevzara | $26 | $68,31816 claims |
| Lilly USA, LLCOlumiant | $562 | $60,87923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Other nurse practitioner in Wheelersburg
- Paul AdkinsWheelersburg$28K
- Margaret BobonichCleveland$235K
- Mary GallagherWestlake$229K
- Sonia HissettCincinnati$179K
- Ashley TaylorNew Albany$107K
- Beth FaimanCleveland$101K
- Katherine AlexanderColumbus$99K
- Tiffany JonesCincinnati$99K
- Kate NewmanWestlake$78K
- Daniella GerySouth Euclid$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.